ReviewBlood2018
How I treat primary mediastinal B-cell lymphoma.
Review in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 73 citations in OpenAlex.
- 4SCAR2.0: a multi-CAR-T therapy regimen for the treatment of relapsed/refractory B cell lymphomas.Blood cancer journal · 2021Trial
- Immune checkpoint therapy in pediatric and adolescent lymphomas.Haematologica · 2026Review
- Risk factor analysis of 115 children and adolescents with primary mediastinal B-cell lymphoma treated with DA-EPOCH-R.Blood advances · 2026Article
- Real-world outcomes and prognostic factors in primary mediastinal B-cell lymphoma: a multicenter study of 157 patients.Annals of hematology · 2025Article
- Primary Mediastinal B-Cell Lymphoma and [18F]FDG PET/CT: What We Learned and What Is New.Hematology reports · 2025Review
- Real-world data analysis of survival outcomes of patients with primary mediastinal large B-cell lymphoma treated with immunochemotherapy: the role of consolidative radiation therapy.Blood research · 2025Article
- DA-R-EPOCH May Mitigate the Adverse Prognostic Implication of the Diagnosis-to-Treatment Interval (DTI) in Large B-Cell Lymphomas.Clinical lymphoma, myeloma & leukemia · 2025Article
- A diagnostic model based onBMC medical imaging · 2024Article
- Article
- Evolving therapeutic landscape of diffuse large B-cell lymphoma: challenges and aspirations.Discover oncology · 2023Review
- Outcome of Primary Mediastinal Large B Cell Lymphoma Treated with RCHOP.Journal of blood medicine · 2023Article
- Resistance mechanisms of immune checkpoint inhibition in lymphoma: Focusing on the tumor microenvironment.Frontiers in pharmacology · 2023Review
- Biochemical, Enzymatic, and Computational Characterization of Recurrent Somatic Mutations of the Human Protein Tyrosine Phosphatase PTP1B in Primary Mediastinal B Cell Lymphoma.International journal of molecular sciences · 2022Article
- Review
- Primary Mediastinal B-cell Lymphoma Presenting as Chest Pain in a Young Woman and Treated with EPOCH-R.Journal of community hospital internal medicine perspectives · 2022Article
- Less Intensive Regimens May Still Be Suitable for the Initial Treatment of Primary Mediastinal B-Cell Lymphoma in Resource-Limited Settings.Journal of oncology · 2022Article
- An Overview of Selected Rare B-Cell Lymphoproliferative Disorders: Imaging, Histopathologic, and Clinical Features.Cancers · 2021Review
- DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose?Clinical advances in hematology & oncology : H&O · 2021Review
- Primary mediastinal large B cell lymphoma.Thoracic cancer · 2021Review
- PET-guided treatment for personalised therapy of Hodgkin lymphoma and aggressive non-Hodgkin lymphoma.The British journal of radiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The World Health Organization now recognizes primary mediastinal B-cell lymphoma (PMBCL) as a unique clinical and biologic entity. PMBCL is distinct from other B-cell non-Hodgkin lymphoma subtypes and has features that overlap with classical Hodgkin lymphoma, including a peak incidence in the adolescent and young adult population, mediastinal presentation of disease, and molecular alterations in JAK2 and programmed death ligands. Because PMBCL is rare, there are few prospective clinical trials to guide therapy, resulting in no single standard of care. Given the long life expectancy of survivors of PMBCL, treatment approaches must balance maximizing cure while minimizing long-term toxicity. In this article, I review my approach to the treatment of PMBCL, incorporating data from adult and pediatric studies, as well as recent advances in our understanding of the molecular basis of PMBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.